The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it none, with a mean price target of $52.
Origin Bancorp, Inc.
OBK · the NYSE · USD · Market cap $1.6B · 1,000 employees
Origin Bancorp, Inc.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price54.06 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.06)
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $52.56 to $87.59, base estimate $62.00 (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.06, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Origin Bancorp, Inc. holds its Markup at $54.06. Consolidating, no directional conviction, held for 1 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 1 days |
| Price at the screen | $54.06 |
| Valuation | 12.99 trailing · 11.51 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 0.73 |
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: bank
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Prohibited keyword in sector/industry: bank | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Origin Bancorp, does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when OBK's ethical verdict changes
Today OBK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 13% discount to our $62.00 fair value, 51.50% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 12.8% discount to the base estimate.
Third-party analyst targets: 5 covering, consensus Buy. The average target sits +15% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $62.00, with a range of $52.56 to $87.59, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsBanks Always Fail Our Ethical Screen
Every time a small business in Texas needs a loan or a municipality in Mississippi parks its cash, the money moves through a regional bank like Origin. We pass on this one outright because it fails our ethical screen on the prohibited bank sector, regardless of the numbers. This is exactly what the screen exists for.
The business shows 9% revenue growth and a 23% profit margin but only a 7% ROE at a forward multiple of 12.3 times, with analysts clustered around a modest buy rating and $55 target against the current price. Those figures do not overcome the ethical block.
Risk sits in heavy regulatory exposure and thin capital returns that leave little room for error in a rising-rate environment. Analysis, not advice.
| Forward P/E | 11.5xcheap for a company growing this fast |
| Trailing P/E | 13.0xreasonably valued |
| EPS, trailing | 4.14 |
| EPS, forward | 4.67 |
| Revenue growth | +51.5%growing very fast |
| Profit margin | 31.1%highly profitable on every dollar of sales |
| Return on equity | 10.4%a modest return on shareholder capital |
| Dividend yield | 2.11% |
| Beta | 0.73steadier than the market |
| Short interest, float | 0.03% |
| 52-week range | 32.28 - 58.00 |
| Market cap | $1.6B |
| Employees | 1,000 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeOBK trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it none, with a mean price target of $52.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 41%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it none, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Earnings Beat Could Change The Case For Origin Bancorp Stock Yahoo Finance · 10d ago
- What Origin Bancorp (OBK) Said on Its Q3 Earnings Call Yahoo Finance · 17d ago
- Origin Bancorp, Inc. Q3 2026 Earnings Call Summary Yahoo Finance · 19d ago
- Origin Bancorp (OBK) Beats Q3 Earnings and Revenue Estimates Yahoo Finance · 19d ago
- Origin Bancorp (OBK) Reports Q3 Earnings: What Key Metrics Have to Say Yahoo Finance · 19d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $45.95 | +6.9% | $0.25 | $1,074 | +7.4% |
| 2 months | $44.56 | +10.2% | $0.25 | $1,108 | +10.8% |
| 3 months | $40.59 | +21.0% | $0.25 | $1,216 | +21.6% |
| 6 months | $38.60 | +27.2% | $0.40 | $1,283 | +28.3% |
| 1 year | $34.73 | +41.4% | $0.70 | $1,434 | +43.4% |
| 2 years | $28.31 | +73.4% | $1.30 | $1,780 | +78.0% |
| 3 years | $29.20 | +68.2% | $1.90 | $1,747 | +74.7% |
| 5 years | $40.83 | +20.3% | $3.04 | $1,277 | +27.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever OBK does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.